Year: 2018

The Cátedra Extraordinaria del Dolor honors Francisco Ciruela for the design of the first photoactive drug with analgesic action

Professor Francisco Ciruela, from the Faculty of Medicine and Health Sciences of the University of Barcelona, the Institute of Neurosciences of the UB and the Bellvitge Biomedical Research Institute (IDIBELL), has been awarded the Preclinical Research Award from Cátedra Extraordinaria del Dolor of the University of Salamanca – Grünenthal Foundation. This prize awards a research with animal models, published in the …

The Cátedra Extraordinaria del Dolor honors Francisco Ciruela for the design of the first photoactive drug with analgesic action Read More »

Successful first #Lindibell swing jam for biomedical research

Last Saturday, January 27th, the Casino of the Center of l’Hospitalet hosted the first Lindibell charity swing jam, the benefits of which will be used to fund some activitites for the young researchers from the Bellvitge Biomedical Research Institute of Bellvitge (IDIBELL). In this first edition, the initiative has raised € 550 thanks to the …

Successful first #Lindibell swing jam for biomedical research Read More »

Researchers identify a new NF-kB pathway regulatory mechanism linked to SirT6

Researchers from the Epigenetics and Cancer Biology Program of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Àlex Vaquero, have proposed a new regulation mechanism of the NF-κB pathway, which is associated with accelerated cellular aging, based on the analysis of the function of the SirT6 protein. The results of their work, published in …

Researchers identify a new NF-kB pathway regulatory mechanism linked to SirT6 Read More »

Conxi Lázaro, Juani Fernández and Alberto Villanueva receive an NF Research Initiative grant to test combination therapies in MPNST

The group of dr. Conxi Lázaro, principal investigator of the Hereditary cancer research group of the Oncobell program (IDIBELL) and head of the Molecular diagnostic Unit of the Hereditary cancer program (ICO), has been awarded one of five preclinical research grants that NF Research Initiative, an initiative linked to Boston Children Hospital, annually offers. This …

Conxi Lázaro, Juani Fernández and Alberto Villanueva receive an NF Research Initiative grant to test combination therapies in MPNST Read More »

IDIBELL researchers successfully test a new combination therapy in sarcomas

Researchers of the Sarcoma group of the Oncobell program – Bellvitge Biomedical Research Institute (IDIBELL) have successfully tested a new combined therapy for the treatment of this rare, aggressive tumor type, which affects children and adults. The results of the clinical trial, published in Targeted Oncology, represent a successful step in the translational research strategy …

IDIBELL researchers successfully test a new combination therapy in sarcomas Read More »

IDIBELL-ICO researchers identify a new therapeutic target to fight metastasis in ovarian cancer

Researchers of the Molecular Signaling in Cancer group of the Oncobell program (Bellvitge Biomedical Research Institute – IDIBELL) – proCURE Program (Catalan Institute of Oncology – ICO) have described a key cellular receptor in the processes of metastasis in ovarian cancer. The finding, published in Molecular Cancer Therapeutics, might lead to the use of inhibitors …

IDIBELL-ICO researchers identify a new therapeutic target to fight metastasis in ovarian cancer Read More »

Scroll to Top